From WikiProjectMed
Jump to navigation Jump to search

Aztreonam structure.svg
Trade namesAzactam, Cayston, others
  • 2-{[(1Z)-1-(2-Amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy-2-methylpropanoic acid
Clinical data
  • AU: B1
Routes of
Intravenous, intramuscular, inhalation
Defined daily dose0.2 gram (inhalation)
4 gram (by injection)[1]
External links
License data
Legal status
Bioavailability100% (IM) 0.1% (by mouth in rats) Unknown (by mouth in humans)
Protein binding56%
MetabolismLiver (minor %)
Elimination half-life1.7 hours
Chemical and physical data
Molar mass435.43 g·mol−1
3D model (JSmol)
Melting point227 °C (441 °F) (dec.)
  • O=S(=O)(O)N2C(=O)[C@@H](NC(=O)C(=N\OC(C(=O)O)(C)C)/c1nc(sc1)N)[C@@H]2C
  • InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1 checkY

Aztreonam, sold under the brand name Azactam among others, is an antibiotic used primarily to treat infections caused by gram-negative bacteria such as Pseudomonas aeruginosa.[2][3] This may include bone infections, endometritis, intra abdominal infections, pneumonia, urinary tract infections, and sepsis.[2] It is given by injection into a vein or muscle or breathed in as a mist.[2]

Common side effects when given by injection include pain at the site of injection, vomiting, and rash.[2] Common side effects when inhaled include wheezing, cough, and vomiting.[2] Serious side effects include Clostridium difficile infection and allergic reactions including anaphylaxis.[2] Those who are allergic to other β-lactam have a low rate of allergy to aztreonam.[2] Use in pregnancy appears to be safe.[2] It is in the monobactam family of medications.[2] Aztreonam usually results in bacterial death through blocking their ability to make a cell wall.[2]

Aztreonam was approved for medical use in the United States in 1986.[2] It was removed from the World Health Organization's List of Essential Medicines in 2019.[4][5] It is available as a generic medication.[2] In the UK the injectable form costs the NHS about £28 per day while the inhaled form costs about £2,182 for a course of treatment.[3] It is a manufactured version of a chemical from the bacterium Chromobacterium violaceum.[6]

Medical uses

Nebulized forms of aztreonam are used to treat infections that are complications of cystic fibrosis and are approved for such use in Europe and the US; they are also used off-label for non-CF bronchiectasis, ventilator-associated pneumonia, chronic obstructive pulmonary disease, mycobacterial disease, and to treat infections in people who have received lung transplants.[7]

Spectrum of activity

Escherichia coli, Pseudomonas aeruginosa, and Proteus mirabilis are generally susceptible to aztreonam[8], while some bacteria have resistance toward it[9]. Furthermore, Enterobacter cloacae, Serratia marcescens, Citrobacter freundii have developed resistance to aztreonam to varying degrees.[10]Aztreonam is often used in people who are penicillin allergic or who cannot tolerate aminoglycosides.[11]

Aztreonam has strong activity against susceptible Gram-negative bacteria, including Pseudomonas aeruginosa,[12] it is resistant to some beta-lactamases[13]

It has no useful activity against Gram-positive bacteria or anaerobes. It is known to be effective against a wide range of bacteria including Citrobacter, Enterobacter, E. coli, Haemophilus, Klebsiella, Proteus, and Serratia species.[14] The following represents MIC susceptibility data for a few medically significant microorganisms.[15]

  • Staphylococcus aureus 8 - >128 μg/ml
  • Staphylococcus epidermidis 8 - 32 μg/ml
  • Streptococcus pyogenes 8 - ≥128 μg/ml

Synergism between aztreonam and arbekacin or tobramycin against P. aeruginosa has been suggested in a 1992 article[16]


The defined daily dose is 0.2 gram (inhalation) or 4 gram (by injection).[1]

Aztreonam is poorly absorbed when given by mouth, so it must be administered parenterally (as an intravenous or intramuscular injection, or inhaled using an ultrasonic nebulizer[17]).[18] In the United States, it was approved for inhalation in 2010, for the suppression of P. aeruginosa infections in people with cystic fibrosis.[19] It received conditional approval for administration in Canada and the European Union in 2009,[19] and has been fully approved in Australia.[20]

Side effects

Reported side effects include injection site reactions, rash, and rarely toxic epidermal necrolysis. Gastrointestinal side effects generally include diarrhea and nausea and vomiting. There may be drug-induced eosinophilia. Because of the unfused beta-lactam ring unique to aztreonam, there is somewhat lower cross-reactivity between aztreonam and many other beta-lactam antibiotics, and it may be safe to administer aztreonam to many patients with hypersensitivity (allergies) to penicillins and nearly all cephalosporins.[21] However, like other beta lactams, there is a risk of serious allergic reactions, including anaphylaxis.[22] This is more likely if the patient is allergic to a certain cephalosporin known as ceftazidime. Aztreonam exhibits cross-reactivity with this cephalosporin due to a similar side chain.[23] [22]

Special caution is warranted in patients who are allergic to ceftazidime and are subsequently placed on aztreonam therapy.[24]

Mechanism of action

Aztreonam is similar in action to penicillin. It inhibits synthesis of the bacterial cell wall, by blocking peptidoglycan crosslinking. It has a very high affinity for penicillin-binding protein-3 and mild affinity for penicillin-binding protein-1a. Aztreonam binds the penicillin-binding proteins of Gram-positive and anaerobic bacteria very poorly and is largely ineffective against them.[21]


  1. 1.0 1.1 "WHOCC - ATC/DDD Index". Retrieved 12 September 2020. CS1 maint: discouraged parameter (link)
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 "Aztreonam". The American Society of Health-System Pharmacists. Retrieved 8 December 2017.
  3. 3.0 3.1 British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 381. ISBN 9780857111562.
  4. World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
  5. World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
  6. Yaffe, Sumner J.; Aranda, Jacob V. (2010). Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice. Lippincott Williams & Wilkins. p. 438. ISBN 9780781795388. Unknown parameter |name-list-format= ignored (help)
  7. Quon BS, Goss CH, Ramsey BW (March 2014). "Inhaled antibiotics for lower airway infections". Annals of the American Thoracic Society. 11 (3): 425–34. doi:10.1513/annalsats.201311-395fr. PMC 4028738. PMID 24673698.
  8. Dowd, Frank J.; Yagiela, John A.; Johnson, Bart; Mariotti, Angelo; Neidle, Enid A. (2010). Pharmacology and Therapeutics for Dentistry - E-Book. Elsevier Health Sciences. p. 618. ISBN 978-0-323-07824-5. Retrieved 27 December 2020. CS1 maint: discouraged parameter (link)
  9. Asensio, Juan A.; Trunkey, Donald D. (2008). Current Therapy of Trauma and Surgical Critical Care E-Book. Elsevier Health Sciences. p. 693. ISBN 978-0-323-07086-7.
  10. Grayson, M. Lindsay; Cosgrove, Sara E.; Crowe, Suzanne; Hope, William; McCarthy, James S.; Mills, John; Mouton, Johan W.; Paterson, David L. Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set. CRC Press. p. 645. ISBN 978-1-4987-4796-7. Retrieved 28 December 2020. CS1 maint: discouraged parameter (link)
  11. Paw, Henry; Shulman, Rob (2019). Handbook of Drugs in Intensive Care: An A-Z Guide. Cambridge University Press. p. 35. ISBN 978-1-108-44435-4. Retrieved 25 December 2020. CS1 maint: discouraged parameter (link)
  12. Doan, Trinh L.; Pollastri, Michael; Walters, Michael A.; Georg, Gunda I. (2011). "Chapter 23 - The Future of Drug Repositioning: Old Drugs, New Opportunities". Annual Reports in Medicinal Chemistry. Academic Press. pp. 385–401. Retrieved 22 December 2020. CS1 maint: discouraged parameter (link)
  13. "Azactam". Retrieved 23 December 2020. CS1 maint: discouraged parameter (link)
  14. Mosby's Drug Consult 2006 (16th ed.). Mosby, Inc. 2006.
  15. Amirkia, Vafa David; Qiubao, Pan (22 January 2011). "The Antimicrobial Index: a comprehensive literature-based antimicrobial database and reference work". Bioinformation. 5 (8): 365–366. ISSN 0973-2063. Retrieved 28 December 2020. CS1 maint: discouraged parameter (link)
  16. Kobayashi, Y.; Uchida, H.; Kawakami, Y. (December 1992). "Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood". The Journal of Antimicrobial Chemotherapy. 30 (6): 871–872. doi:10.1093/jac/30.6.871. ISSN 0305-7453. Retrieved 28 December 2020. CS1 maint: discouraged parameter (link)
  17. "Aztreonam Dosage Guide with Precautions". Retrieved 18 December 2020. CS1 maint: discouraged parameter (link)
  18. Ritter, James; Lewis, Lionel; Mant, Timothy; Ferro, Albert. A Textbook of Clinical Pharmacology and Therapeutics, 5Ed. CRC Press. p. 327. ISBN 978-1-4441-1300-6. Retrieved 18 December 2020. CS1 maint: discouraged parameter (link)
  19. 19.0 19.1 Larkin, Catherine (22 February 2010). "Gilead's Inhaled Antibiotic for Lungs Wins Approval". BusinessWeek. Archived from the original on 2 March 2010. Retrieved 5 March 2010. Unknown parameter |name-list-format= ignored (help)
  20. "FDA approves Gilead cystic fibrosis drug Cayston". BusinessWeek. 23 February 2010. Retrieved 5 March 2010.
  21. 21.0 21.1 AHFS Drug Information 2006 (2006 ed.). American Society of Health-System Pharmacists. 2006.
  22. 22.0 22.1 "Aztreonam Side Effects: Common, Severe, Long Term". Retrieved 27 December 2020. CS1 maint: discouraged parameter (link)
  23. Chaudhry, Saira B.; Veve, Michael P.; Wagner, Jamie L. (29 July 2019). "Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity". Pharmacy: Journal of Pharmacy Education and Practice. 7 (3). doi:10.3390/pharmacy7030103. ISSN 2226-4787. Retrieved 27 December 2020. CS1 maint: discouraged parameter (link)
  24. James, Christopher W.; Gurk-Turner, Cheryle (2001). "Cross-reactivity of beta-lactam antibiotics". Proceedings (Baylor University. Medical Center). 14 (1): 106–107. ISSN 0899-8280. Retrieved 19 December 2020. CS1 maint: discouraged parameter (link)

External links

  • "Aztreonam". Drug Information Portal. U.S. National Library of Medicine.